Hepatocyte growth factor and its receptor signalling complex as targets in cancer therapy

Martin, Tracey Amanda ORCID: https://orcid.org/0000-0003-2690-4908 and Jiang, Wen Guo ORCID: https://orcid.org/0000-0002-3283-1111 2010. Hepatocyte growth factor and its receptor signalling complex as targets in cancer therapy. Anti-Cancer Agents in Medicinal Chemistry 10 (1) , pp. 2-6.

Full text not available from this repository.

Abstract

Hepatocyte growth factor (HGF) and it's receptor, cMET, have become the focus on intense scrutiny since its discovery in the late 1980s [1, 2] as regards it role in cancer. HGF is now known to be a potent morphogen that can regulate tissue and organ regeneration and modulate cell morphology, it is a motogen that can stimulate cell motility and migration, and is a mitogen able to regulate cell growth and death and as an angiogenic factor [3]. HGF is can induce both angiogenesis and lymphangiogenesis [3a; 4]. That HGF and cMET have such a diversity of functions has led to intense interest in the clinical setting due to their potential in their prognostic aspect and therapeutic implications as imaging tools. This issue will focus on recent work that shows strong indications for the value of HGF and cMET in clinical settings.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Subjects:	R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Uncontrolled Keywords:	Hepatocyte growth factor, cMET, angiogenesis, metastasis, imaging, cancer treatment
Publisher:	Bentham Science
ISSN:	1875-5992
Last Modified:	19 Oct 2022 08:37
URI:	https://orca.cardiff.ac.uk/id/eprint/18431

Citation Data

Cited 37 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item